Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    Advanced Search
    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Canadian Federal Government
        • Canadian Municipal Government
        • Canadian Provincial Government
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Advanced Search
    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • IR
    • All Products
    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media
    • Worldwide Offices
    • Hamburger menu
    • Cision Canada
    • Send a Release
    • FR
      • Phone

      • 877-269-7890 from 8 AM - 10 PM ET

      • ALL CONTACT INFO
      • Contact Cision

        877-269-7890
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • 3 News in Focus
      • 5 Business
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • IR
      • All Products
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media
      • Worldwide Offices
      • General Enquiries
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business) Business
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cipher Pharmaceuticals Reports First Quarter 2025 Results, and Announces $15 Million Debt Repayment


      News provided by

      Cipher Pharmaceuticals Inc.

      May 08, 2025, 17:00 ET

      Share this article

      Share this article


      (All figures are presented in U.S. Dollars)

      • Adjusted EBITDA2 in Q1 2025 was $6.2 million, an increase of 73% over Q1 2024
      • Canadian product portfolio sales volumes grew 46% in the quarter compared to Q1 2024
      • NatrobaTM sales were $6.7 million during the quarter, a sequential increase of 3% over Q4 2024
      • Continued strong track record of cash generation with $4.2 million cash from operations in Q1 2025
      • $22.0 million cash balance at the end of Q1 2025
      • $15.0 million debt repayment subsequent to Q1 2025

      MISSISSAUGA, ON, May 8, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced its financial and operating results for the three months ended March 31, 2025.

      First Quarter 2025 Financial Highlights
      (All figures in U.S. dollars, compared to Q1 2024, unless otherwise noted)

      • Total revenue was $12.0 million in Q1 2025, an increase of 105%
      • Canadian product portfolio revenue increased by 41% to $4.6 million in Q1 2025, compared to $3.3 million in Q1 2024
      • NatrobaTM provided $6.7 million of incremental product revenue in Q1 2025
      • Licensing revenue was $0.7 million in Q1 2025, a decrease of $1.9 million, due to lower product shipments to licensing partners, combined with lower partner sales volumes and royalty rates
      • Total gross profit from operations increased by 90% to $9.1 million in Q1 2025
      • Adjusted EBITDA2 increased 73% to $6.2 million in Q1 2025

      Management Commentary

      Craig Mull, Interim CEO, commented: "Our Canadian product portfolio continued to demonstrate strong performance in Q1 2025, with consecutive quarter revenue growth of 15% and 41% revenue growth compared to the same quarter in the prior year. Our Canadian product portfolio continues to be a reliable source of revenue for Cipher.

      Natroba™ has performed consistent with our expectations from when we acquired the product this past July, and we believe the product's revenue in Q1 2025 has positioned the business well to start 2025, given the seasonality for the product results in generally lower demand during the colder months of the calendar year, and higher demand for the product in the upcoming warmer months of the year."

      Ryan Mailling, CFO, commented: "In Q1 2025, our base business in Canada, combined with the NatrobaTM business in the US, continued to generate free cash flow for Cipher, with $4.2 million of cash generated from operations during the quarter, and an ending cash balance of $22.0 million. As we have demonstrated previously, we will continue to be smart in our approach to allocating capital, with the ability to return capital to shareholders through our recently approved Normal Course Issuer Bid ("NCIB"); by further de-levering the Company's current low leverage position through repayments on our revolving credit facility; and by continuing to be selective in our approach to executing on acquisition opportunities."

      Corporate Highlights

      • On April 29, 2025, Cipher announced its product NatrobaTM received preferred step-through status on Medicaid in the state of Illinois, whereby its main product competitor Permethrin 5% was downgraded to non-preferred on the state's preferred drug listing. This move by Illinois Medicaid will require all prescriptions for Permethrin 5% to first 'step-though' NatrobaTM representing the treatment of choice in the state.
      • On May 1, 2025, Cipher announced that the Toronto Stock Exchange (the "TSX") has approved the Company's Notice of Intention to Make a Normal Course Issuer Bid under which the Company may purchase for cancellation, from time to time up to May 4, 2026, up to an aggregate of 1,485,260 of its issued and outstanding common shares, being 10% of its public float of 14,852,604 common shares as of April 22, 2025. In accordance with TSX rules, any daily repurchases on the TSX under the NCIB are limited to a maximum of 10,427 common shares, which represents 25% of the average daily trading volume on the TSX of 41,708 for the six months ended March 31, 2025. To facilitate larger repurchases, the Company is entitled to make one weekly block purchase on the TSX that may exceed the daily repurchase restrictions, and the Company intends to exercise this entitlement.
      • On May 8, 2025, the Company repaid $15.0 million of the outstanding balance on its revolving credit facility. As a result of the repayment, the outstanding balance on the Company's revolving credit facility has been reduced to $25.0 million as of May 8, 2025. Due to the revolving nature of the credit facility, an additional $40.0 million remains available to the Company to draw upon, should financing be required.

      Q1 2025 Financial Review

      (All figures in U.S. dollars, compared to Q1 2024, unless otherwise noted)

      • Total revenue was $12.0 million in Q1 2025, compared to $5.9 million in Q1 2024, an increase of 105%
      • In constant currency, Canadian product portfolio revenue increased by 50%
      • Product revenue from the Canadian product portfolio was $4.6 million in Q1 2025, an increase from $3.3 million in Q1 2024
      • Product revenue from NatrobaTM in the U.S. was $6.7 million, up from $6.5 million sequentially from Q4 2024 whereby the product was acquired on July 29, 2024
      • Licensing revenue decreased 72% to $0.7 million in Q1 2025 compared to $2.6 million in Q1 2024, impacted by reduced product shipments to licensing partners; lower net sales realized by Cipher's partners on which the Company earns a royalty; and contractual royalty rate reductions
      • Total gross profit was $9.1 million in Q1 2025, compared to $4.8 million in Q1 2024, an increase of 90%
      • Gross margin decreased by 6% to 76% in Q1 2025 from 82% in Q1 2024 due to a lower proportion of royalty licensing revenue during the quarter, and the impact of non-cash fair value adjustments on acquired Natroba™ inventory which had carried over into Q1 2025 as the inventory was sold
      • Gross margin as a percentage of product revenue increased by 6% to 74% in Q1 2025 from 68% in Q1 2024
      • Net income and earnings per common share were $2.6 million and $0.10, respectively, in Q1 2025, compared to $4.9 million and $0.21 in Q1 2024, with the decrease primarily attributable to the amount of non-cash deferred tax losses recognized in Q1 2024 compared to Q1 2025
      • EBITDA2 in Q1 2025 was $4.2 million, compared to $2.7 million in Q1 2024, an increase of 55%
      • Adjusted EBITDA2 in Q1 2025 was $6.2 million, compared to $3.6 million in Q1 2024, an increase of $2.6 million or 73%

      Business Strategy & Outlook

      Cipher expects to continue to execute on its business strategy, remains focused on profitability and delivering shareholder value. Key areas of focus include:

      • Driving market share growth of Natroba™ in the anti-parasitic market in the U.S. where its current market share is approximately 23%3, in a market where market leader "Permethrin" is no longer an effective treatment but still holds 75%3 market share.
      • Out-licensing Natroba™ globally where there is high unmet need, such as warm climate regions.
      • Acquiring complementary dermatology products to add to our North American platform to enhance the profitability, size and scale of the business.

      Financial Statements and MD&A

      Cipher's Financial Statements for the three months ended March 31, 2025, and Management's Discussion and Analysis (the "MD&A") for the three months ended March 31, 2025, are available on the Company's website at www.cipherpharma.com in the "Investors" section under "Financial Reports" and on SEDAR+ at www.sedarplus.ca.

      Notice of Conference Call

      Cipher will hold a conference call on May 9, 2025 at 8:30 a.m. (ET) to discuss its financial results and other corporate developments.

      • To access the conference call by telephone, dial (416) 945-7677 or (888) 699-1199
      • A live audio webcast will be available at https://app.webinar.net/9dwb3Zn3Qap
      • An archived replay of the webcast will be available until May 16, 2025 and can be accessed by dialing (289) 819-1450 or (888) 660-6345 and entering conference replay code 69080#

      About Cipher Pharmaceuticals Inc.

      Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.

      Forward-Looking Statements and Non-IFRS Measures

      This document includes forward-looking statements within the meaning of applicable securities laws. These forward-looking statements include, among others, expectations for future growth, objectives and goals and strategies to achieve those objectives and goals, the potential purchases to be made under the NCIB, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates and intentions.  The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. By their nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. We caution readers not to place undue reliance on these statements as a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to, our ability to enter into development, manufacturing and marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our dependency on a limited number of products; our dependency on protection from patents that will expire; the extent and impact of health pandemic outbreaks on our business; integration difficulties and other risks if we acquire or in-license technologies or product candidates; reliance on third parties for the marketing of certain products; the product approval process by regulators which can be highly unpredictable; the timing of completion of clinical trials, regulatory submissions and regulatory approvals; reliance on third parties to manufacture our products and events outside of our control that could adversely impact the ability of our manufacturing partners to supply products to meet our demands; we may be subject to future product liability claims; unexpected product safety or efficacy concerns may arise; we generate license revenue from a limited number of distribution and supply agreements; the Company's performance depends, in part, on the performance of its distributors and suppliers; the pharmaceutical industry is highly competitive with new competing product entrants; requirements for additional capital to fund future operations; products may be subject to pricing regulation; dependence on key managerial personnel and external collaborators; the ability to receive regulatory approvals for products in development or future products; certain of our products are subject to regulation as controlled substances; limitations on reimbursement in the healthcare industry; the ability to convince public payors and hospitals to include our products on the approved formulary lists; ability to receive timely payment from certain customers; application of various laws pertaining to health care fraud and abuse; the Company's reliance on the success of strategic investments and partnerships; the publication of negative results of clinical trials; unpredictable development goals and projected time frames; rising insurance costs; ability to enforce covenants not to compete; risks associated with the healthcare industry generally; we may be unsuccessful in evaluating material risks involved in completed and future acquisitions; we may be unable to identify, acquire or integrate acquisition targets successfully; success in applying tax loss carry forwards; inability to meet covenants under our long-term debt arrangement; compliance with privacy and security regulation; our policies regarding product returns, allowances and chargebacks may reduce revenues; additional regulatory burden and controls over financial reporting; application of regulations that could restrict our activities and abilities to generate revenues as planned; reliance on third parties to perform distribution, logistics, invoicing, regulatory and sales services; general commercial litigation, class actions, other litigation claims and regulatory actions; the difficulty for shareholders to realize in the United States upon judgments of U.S. courts predicated upon civil liability of the Company and its directors and officers who are not residents of the United States; increases in tariffs, trade restrictions or taxes on our products; the potential violation of intellectual property rights of third parties; our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our products; changes in U.S., Canadian or foreign patent laws; inability to protect our trademarks from infringement; shareholders may be further diluted if we issue securities to raise capital; volatility of our share price; the fact that we have a significant shareholder; our operating results may fluctuate significantly; and our debt obligations will have priority over the common shares of the Company in the event of a liquidation, dissolution or winding up.  We caution that the foregoing list of important factors that may affect future results is not exhaustive. When reviewing our forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Additional information about factors that may cause actual results to differ materially from expectations, and about material factors or assumptions applied in making forward-looking statements, may be found in the "Risk Factors" section of our MD&A for the year ended December 31, 2024 and the Company's Annual Information Form, and elsewhere in our filings with Canadian securities regulators. Except as required by Canadian securities law, we do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language.

      1. At the March 31, 2025 exchange rate – 1.4376

      2. EBITDA and adjusted EBITDA are non-IFRS financial measures.  These non-IFRS measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are unlikely to be comparable to similar measures presented by other companies. Management uses non-IFRS measures such as Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA") and Adjusted EBITDA to provide investors with supplemental measures of the Company's operating performance and thus highlight trends in the Company's core business that may not otherwise be apparent when relying solely on IFRS financial measures.  The Company defines Adjusted EBITDA as earnings before interest expense, income taxes, depreciation of property and equipment, amortization of intangible assets, non-cash share-based compensation, changes in fair value of derivative financial instruments, costs and provisions for legal matters, costs associated with arbitration, loss on disposal of assets and loss on extinguishment of lease, impairment of intangible assets, acquisition costs, restructuring costs, fair value adjustments to acquired inventory and unrealized foreign exchange gains and losses.

      3. IQVIA market data as at March 31, 2025.

      The following is a summary of how EBITDA and Adjusted EBITDA are calculated:

      (IN THOUSANDS OF U.S. DOLLARS,

      Three months
      ended

      March 31, 2025

      Three months
      ended

      March 31, 2024 

      except for per share amounts)

      $

      $




      Net income and comprehensive income

      2,624

      4,923

      Add back:



      Depreciation and amortization

      1,822

      289

      Interest expense (income)

      470

      (555)

      Income tax recovery

      (737)

      (1,955)

      EBITDA

      4,179

      2,702




      Unrealized foreign exchange (gain) loss

      (11)

      642

      Acquisition, restructuring and other costs

      128

      —

      Fair value adjustments to acquired inventory

      646

      —

      Costs and provisions for legal matters

      1,000

      —

      Share-based compensation

      244

      224

      Adjusted EBITDA

      6,186

      3,568

      Adjusted EBITDA per share – basic

      0.24

      0.15

      Adjusted EBITDA per share – dilutive

      0.24

      0.15

      Consolidated statements of income and comprehensive income


      Three months

      ended March 31,

      (IN THOUSANDS OF U.S. DOLLARS,

      2025

      2024

      except for per share amounts)

      $

      $




      Revenue



      Licensing revenue

      735

      2,600

      Product revenue

      11,284

      3,267

      Net revenue

      12,019

      5,867




      Operating expenses



      Cost of products sold

      2,879

      1,055

      Research and development

      21

      —

      Depreciation and amortization

      1,822

      289

      Selling, general and administrative

      4,951

      1,468

      Total operating expenses

      9,673

      2,812




      Other expenses (income)



      Interest expense (income)

      470

      (555)

      Unrealized foreign exchange (gain) loss

      (11)

      642

      Total other expenses (income)

      459

      87




      Income before income taxes

      1,887

      2,968




      Current income tax expense

      —

      —

      Deferred income tax recovery

      (737)

      (1,955)

      Total income tax recovery

      (737)

      (1,955)




      Net income and comprehensive income for the period

      2,624

      4,923







      Income per share



      Basic

      0.10

      0.21

      Diluted

      0.10

      0.20

      Consolidated statements of financial position


      As at March 31,

      As at December 31,


      2025

      2024

      (IN THOUSANDS OF U.S. DOLLARS)

      $

      $

      Assets






      Current assets



      Cash and cash equivalents

      22,000

      17,837

      Accounts receivable

      11,773

      13,860

      Inventory

      5,535

      5,792

      Prepaid expenses and other assets

      837

      995

      Total current assets

      40,145

      38,484

      Property and equipment

      602

      680

      Intangible assets

      77,013

      78,754

      Deferred financing costs

      348

      386

      Goodwill

      17,447

      17,447

      Deferred tax assets

      27,519

      26,761

      Total assets

      163,074

      162,512




      Liabilities and shareholders' equity






      Current liabilities



      Accounts payable and accrued liabilities

      5,299

      5,873

      Income taxes payable

      54

      54

      Interest payable

      330

      358

      Contract liabilities

      11,637

      13,306

      Current portion of lease obligation

      267

      283

      Total current liabilities

      17,587

      19,874

      Lease obligation

      245

      295

      Long-term debt

      40,000

      40,000

      Total liabilities

      57,832

      60,169




      Shareholders' equity



      Share capital

      27,767

      27,680

      Contributed surplus

      6,713

      6,525

      Accumulated other comprehensive loss

      (9,514)

      (9,514)

      Retained earnings

      80,276

      77,652

      Total shareholders' equity

      105,242

      102,343

      Total liabilities and shareholders' equity

      163,074

      162,512

      SOURCE Cipher Pharmaceuticals Inc.

      For further information: Graham Farrell, Investor Relations - Cipher Pharmaceuticals, [email protected], 416-842-9003

      Modal title

      Organization Profile

      Cipher Pharmaceuticals Inc.

        Also from this source

      • Cipher Pharmaceuticals Reports Third Quarter 2026 Results

      • Cipher Pharmaceuticals Schedules Q3 2026 Earnings Release and Conference Call

      • Cipher Pharmaceuticals Announces the Appointment of Rajiv De Silva to its Board of Directors

      Contact PR Newswire

      • 866-245-2317
        from 7:30 AM - 6:30 PM ET
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • Investor Relations

      About

      • About PR Newswire
      • About Cision
      • Careers
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • Platform Login
      • Privacy Policy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      • Next Gen Communications Cloud
      • Cision Communications Cloud
      • my CNW
      877-269-7890
      from 8 AM - 10 PM ET
      • Terms of Use
      • Information Security Policy
      • Site Map
      • Cookie Settings
      • Accessibility Statement
      Copyright © 2026 CNW Group Ltd. All Rights Reserved. A Cision company.